Search results
Results from the WOW.Com Content Network
Hormonal therapies to reduce or stop menstrual bleeding have long been used to manage a number of gynecologic conditions including menstrual cramps (dysmenorrhea), heavy menstrual bleeding, irregular or other abnormal uterine bleeding, menstrual-related mood changes (premenstrual syndrome or premenstrual dysphoric disorder), and pelvic pain due to endometriosis or uterine fibroids.
Medroxyprogesterone, also known as 6α-methyl-17α-hydroxyprogesterone or as 6α-methyl-17α-hydroxypregn-4-en-3,20-dione, is a synthetic pregnane steroid and a derivative of progesterone. [ 2 ] [ 3 ] It is specifically a derivative of 17α-hydroxyprogesterone with a methyl group at the C6α position.
Medroxyprogesterone acetate (MPA), also known as depot medroxyprogesterone acetate (DMPA) in injectable form and sold under the brand name Depo-Provera among others, is a hormonal medication of the progestin type. [10] [4] It is used as a method of birth control and as a part of menopausal hormone therapy.
Medroxyprogesterone acetate (brand names Depo-Provera, Provera, Depo-subQ Provera 104) [4] – 150 mg (intramuscularly) or 104 mg (subcutaneously) every 3 months [3] Norethisterone enanthate (brand names NET EN, Noristerat, Norigest, Doryxas) [ 5 ] – 200 mg (intramuscularly) every 2 months [ 3 ]
Delay in starting the next packet of active pills (i.e., extending the pill-free, inactive pill or placebo pill period beyond 7 days), Intestinal malabsorption of active pills due to vomiting or diarrhea, Drug-drug interactions among COCPs and other medications of the user that decrease contraceptive estrogen and/or progestogen levels. [44]
"What we know is there is a sensitivity or an allergy that seems to be a reaction to the high progesterone levels that occur during the luteal phase, which is directly before the menstrual period ...
Combined hormonal contraception (CHC), or combined birth control, is a form of hormonal contraception which combines both an estrogen and a progestogen in varying formulations.
Template:Medications and dosages used in hormone therapy for transgender men References ^ Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (November 2017).